Navigation Links
Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
Date:10/27/2009

EMERYVILLE, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host a webcast and teleconference with management to provide a general business overview, as well as to discuss third quarter 2009 financial results, on Tuesday, November 3, 2009, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Financial results for the third quarter ended September 30, 2009 will be released earlier that day.

Interested parties may access a live webcast of the presentation on the company's website at: http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

or by dialing 847-619-6547 and using the passcode 25674242. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 25674242 approximately one hour after the teleconference concludes. The replay will be available through December 3, 2009.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar®, a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals.

SOURCE Onyx Pharmaceuticals, Inc.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
2. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
3. Bellicum Pharmaceuticals Announces $4.5 Million in New Funding
4. BioMarin Acquires Huxley Pharmaceuticals, Inc.
5. Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences
6. Transdel Pharmaceuticals to Webcast Presentation at 4th Annual BIOCOM Investor Conference
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
8. Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
9. Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009
10. Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
11. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)...   Royal Philips (NYSE: ... received 510(k) clearance from the U.S. Food and ... for Transcatheter Aortic-Valve Implantation (TAVI) treatments. Through 3D ... pre-procedural, high-precision positioning to treat aortic stenosis ailments.  ... available as part of Philips IntelliSpace Portal ...
(Date:8/21/2014)... JOSE, Calif. , Aug. 21, 2014  SI-BONE, ... medical device company that pioneered the use of the ... (MIS) device indicated for fusion of the sacroiliac (SI) ... ) published an update to its Lumbar Fusion Medical ... SI joint fusion procedure.  The policy states that the ...
(Date:8/21/2014)... 2014   Auxilium Pharmaceuticals, Inc. (NASDAQ: ... today announced positive results from a randomized, double-blind ... CCH) for the treatment of edematous fibrosclerotic panniculopathy ... 2a trial, all three doses of CCH (low ... improvement in the appearance of cellulite as measured ...
Breaking Medicine Technology:Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7
... May 9 Osteoarthritis is a,painful and ... people in the United States. It is ... The novel investigational pain medication,tapentadol, a centrally ... with joint-disease pain, compared to those treated ...
... Biosciences, Inc.,(Nasdaq: RDEA ), a company focused ... for the treatment of HIV, cancer and,inflammatory diseases, ... been appointed Senior Vice President, Finance and Operations ... will resign from our board of,directors shortly thereafter. ...
Cached Medicine Technology:Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 2Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 3Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 4Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 6
(Date:8/21/2014)... a new review of seafood safety, Consumer Reports is ... concerns about mercury exposure. "We,re particularly concerned about ... the most commonly eaten seafood in the United States. ... Halloran, director of food policy initiatives for Consumers Union, ... news release from the group. While pregnant women ...
(Date:8/21/2014)... 21, 2014 Pleio, Inc., a ... launching a new suite of services for retail ... retail pharmacy by applying proven behavior shaping programs ... in increased medication adherence, higher PDC scores and ... Pleio’s PDC-targeted offerings align retail’s desire to meet ...
(Date:8/21/2014)... 21, 2014) An international scientific collaboration led by ... alterations that may contribute to a rare form of ... rare cancer but other types as well. , The ... Cancer Genome Atlas initiative , completed the sequence ... today in the journal Cancer Cell . ...
(Date:8/21/2014)... SAN FRANCISCO, Aug. 21, 2014 Individuals with schizophrenia ... goals for themselves, and a new study from San ... difficulty in assessing the amount of effort required to ... published this week in the Journal of Abnormal ... deficits among patients with schizophrenia and help those patients ...
(Date:8/21/2014)... Stevin McNamara’s original approach to guitar music is based ... that has existed in India for centuries. Literally meaning “that ... or some fixed sequence of notes, but is considered a ... time of day or season of the year — it ... occurs, in its turn creating an unique “sound manifestation” between ...
Breaking Medicine News(10 mins):Health News:Consumer Reports Advises Pregnant Women to Avoid Tuna 2Health News:Pleio, Inc. Expands Adherence Offerings For Retail Pharmacy 2Health News:Sequence of rare kidney cancer reveals unique alterations involving telomerase 2Health News:Sequence of rare kidney cancer reveals unique alterations involving telomerase 3Health News:Difficulty assessing effort drives motivation deficits in schizophrenia, study finds 2Health News:Raga Cycle of Shakti Guitar Follows The Sun 2Health News:Raga Cycle of Shakti Guitar Follows The Sun 3
... The Michael J. Fox,Foundation (MJFF) for Parkinson,s Research ... effort. Under this annual program the Foundation,will award ... designed to validate the,therapeutic potential of scientific discoveries, ... investment and clinical trials., "Target Validation is ...
... cells in the liver, allowing steatosis (simple fatty liver) ... to the results of a new study in the ... Wiley & Sons on behalf of the American Association ... is also available online at Wiley Interscience (http://www.interscience.wiley.com/journal/hepatology). , ...
... Carrington,Laboratories, Inc. (OTC Bulletin Board: CARN) today ... present,at the Acumen BioFin Rodman & Renshaw 9th ... pm Eastern Time at the New York Palace,Hotel. ... technologies in the,areas of drug delivery and vaccine ...
... NEW YORK, Nov. 1 Fibromyalgia is the ... States, affecting more than,six million Americans. But, findings ... Association (NFA) show there is still much to ... of the general public shows nearly half (45%) ...
... ... Services, DALLAS, Nov. 1 ... the largest gift in the,institution,s 80-year history. The Schenkels, gift today represents ... Schenkels, $4 million gift, the fund now tops the $50,million mark. ...
... is common in children with heart disease, a population ... , More than 25 percent of children with ... say researchers from The Childrens Hospital of Philadelphia and ... current issue of Pediatrics. While this 25 percent prevalence ...
Cached Medicine News:Health News:Michael J. Fox Foundation Commits Up to $2 Million for PD Drug Development Under Target Validation 2008 2Health News:High-fat diet makes mice susceptible to liver injury 2Health News:Carrington Subsidiary DelSite to Present at Investor Conference 2Health News:Medialink Features: The Painful Truth About Fibromyalgia 2Health News:Methodist Health System Foundation Announces Largest Single Gift 2Health News:Methodist Health System Foundation Announces Largest Single Gift 3Health News:Methodist Health System Foundation Announces Largest Single Gift 4Health News:Obesity common in children with heart disease 2
... Mikro-Tip pressure intravascular catheters provide a ... of measuring pressures in the heart ... Mikro-Tip catheters are ideal for high ... in size from 2 to 7 ...
... Millar Mikro-Tip pressure intravascular catheters provide ... method of measuring pressures in the ... thromboresistant Mikro-Tip catheters are ideal for ... range in size from 2 to ...
... Intravascular Mikro-Tip Pressure Catheters; Millar manufactures ... pressure sensor catheters for simultaneous high ... suitable for measuring pressure gradients across ... a vascular stenosis. The catheters are ...
... the United States dying from Sudden Cardiac Death ... recommended that AEDs be used as a standard ... Any AED can provide a life-saving shock during ... continuous monitoring capabilities during and after resuscitation. Plus ...
Medicine Products: